Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. (Q39778317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

Rift Valley fever phlebovirus

23 January 2020

main subject

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Janice M Rusnak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Paul Gibbs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Ellen Boudreau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Denise P Clizbe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

26 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

3222-3229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Severe Rift Valley fever may present with a characteristic clinical syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Clinical aspects of African viral hemorrhagic fevers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Developing a Research Agenda and a Comprehensive National Prevention and Response Plan for Rift Valley Fever in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever virus vaccine trial: study of side-effects in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift valley fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Experimental Rift Valley fever in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Phylogenetic relationships among sandfly fever group viruses (Phlebovirus: Bunyaviridae) based on the small genome segment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Antigenic and genetic relationships among Rift Valley fever virus and other selected members of the genus Phlebovirus (Bunyaviridae).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Immune response to anti-HBV vaccination: study of conditioning factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Sex differences in the humoral antibody response to live measles vaccine in young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Sexual dimorphism of humoral immunity with human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Anthrax vaccine: short-term safety experience in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Study of the serological response after vaccination against tick-borne encephalitis in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever as a possible cause of human abortions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Rift Valley fever: a sero-epidemiological survey among pregnant women in Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

Studies on the Antigenic Relationship among Phleboviruses *

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

inferred from DOI database lookup

7 January 2021

based on heuristic

Serological tests for detecting Rift Valley fever viral antibodies in sheep from the Nile Delta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.037

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.02.037

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354483%20AND%20SRC:MED&resulttype=core&format=json

release_6nwxhy2hzvefhfxde63qrg4ckq

23 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6nwxhy2hzvefhfxde63qrg4ckq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference